Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sofosbuvir
Drug ID BADD_D02053
Description Sofosbuvir (tradename Sovaldi) is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients [L852]. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as sofosbuvir. As a prodrug nucleotide analog, Sofosbuvir is metabolized into its active form as the antiviral agent 2'-deoxy-2'-α-fluoro-β-C-methyluridine-5'-triphosphate (also known as GS-461203), which acts as a defective substrate for NS5B (non-structural protein 5B) [synthesis]. NS5B, an RNA-dependent RNA polymerase, is essential for the transcription of Hepatitis C viral RNA and for its high replicative rate and genetic diversity [A19594]. Sofosbuvir and other direct acting antivirals are therefore very potent options for the treatment of Hepatitis C, as they exhibit a high barrier to the development of resistance [A19593]. This is an important advantage relative to HCV drugs that target other viral enzymes such as the protease, for which rapid development of resistance has proven to be an important cause of therapeutic failure.
Indications and Usage Resistance: Reduced susceptibility to sofosbuvir has been associated with the NS5B substitution mutation S282T [A19634].
Marketing Status Prescription
ATC Code J05AP08
DrugBank ID DB08934
KEGG ID D10366
MeSH ID D000069474
PubChem ID 45375808
TTD Drug ID D0D4YZ
NDC Product Code 46708-900; 63285-752; 68554-0086; 73637-1505; 73675-001; 59116-4670; 61958-1504; 48087-0120; 73637-1504; 61958-1505; 69218-0200; 50683-0412; 69037-0014; 61958-1503; 61958-1501
Synonyms Sofosbuvir | 2-((5-(2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-ylmethoxy)phenoxyphosphorylamino)propionic acid isopropyl ester | PSI 7977 | 7977, PSI | PSI7977 | PSI-7977 | GS-7977 | GS 7977 | GS7977 | Sovaldi
Chemical Information
Molecular Formula C22H29FN3O9P
CAS Registry Number 1190307-88-0
SMILES CC(C)OC(=O)C(C)NP(=O)(OCC1C(C(C(O1)N2C=CC(=O)NC2=O)(C)F)O)OC3=CC=CC=C3
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Disturbance in attention19.21.02.002; 17.03.03.0010.009403%
Diverticulitis11.01.07.003; 07.10.02.001--Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.0040.070162%
Drug abuse19.07.02.010--Not Available
Drug dependence19.07.02.009--Not Available
Drug hypersensitivity10.01.01.001--Not Available
Drug withdrawal syndrome19.07.02.011; 08.06.02.004--Not Available
Dry eye06.08.02.001--
Dry mouth07.06.01.0020.009403%
Dry skin23.03.03.0010.016636%
Duodenitis07.08.03.0010.001447%Not Available
Dysarthria19.19.03.001; 17.02.08.001--
Dysgeusia07.14.03.001; 17.02.07.003--
Dyskinesia17.01.02.006--
Dyspepsia07.01.02.0010.011573%
Dysphagia07.01.06.003--
Dysphonia22.02.05.005; 19.19.03.002; 17.02.08.004--
Dyspnoea22.02.01.004; 02.01.03.002--
Dyspnoea exertional22.02.01.005; 02.01.03.0030.007957%Not Available
Dysuria20.02.02.002--
Eating disorder19.09.01.008; 14.03.01.008--Not Available
Eczema23.03.04.006--
Emotional disorder19.04.02.0050.004340%Not Available
Encephalopathy17.13.02.0010.013020%
Endocarditis11.01.16.001; 02.09.01.0010.000377%
Epistaxis24.07.01.005; 22.04.03.001--
Erysipelas23.09.01.002; 11.02.06.0010.002893%Not Available
Erythema23.03.06.001--Not Available
Erythema multiforme23.03.01.003; 10.01.03.0150.004340%
Escherichia sepsis11.02.10.0020.000377%Not Available
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 21 Pages